$AAPG News

Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

Ascentage Pharma (SEHK:6855) Stock Looks Above Fair Value After The Fall

William Blair Initiates Coverage On Ascentage Pharma Group with Outperform Rating

Citigroup Initiates Coverage On Ascentage Pharma Group with Buy Rating, Announces Price Target of $46

Citizens Initiates Coverage On Ascentage Pharma Group with Market Outperform Rating, Announces Price Target of $35

JP Morgan Maintains Overweight on Ascentage Pharma Group, Lowers Price Target to $33

Ascentage Pharma to Participate in Four Upcoming Investor Conferences

Ascentage Pharma Group International (SEHK:6855) Could Be 18% Undervalued After Half Year Losses

ASCENTAGE PHARMA GROUP INTERNATIONAL Q2 2026 Earnings Call Summary

BTIG Reiterates Buy on Ascentage Pharma Group, Maintains $48 Price Target

Transcript: Ascentage Pharma Group H1 2026 Earnings Conference Call

Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript

Ascentage Pharma Group International 2026 Q2 - Results - Earnings Call Presentation

Reported Earlier, Ascentage Pharma Group H1 EPS $(0.32) Beats $(0.44) Estimate, Sales $44.541M Beat $24.070M Estimate

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit

CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer

Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know